- Fiat Chrysler CEO Marchionne Possibly on Prowl for a Deal With GM
- NBC Waiting for Brian Williams Apology as Firing Remains Possible
- It's Time for the Eurozone to Let Greece and Tsipras Go
- 'Star Wars' Crushes 'Batman v. Superman' -- and It's Not Even Close
- $15 Minimum Wage Protests Could Spell Major Problem for Retailers
As the CEO of a struggling stem-cell therapy company, Hedrick needs to don brightly colored pom-poms just to grab investors' attention.
Investors were treated to a hepatitis C data dump Wednesday morning ahead of a European liver disease meeting later in the month.
The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.
Plans to seek U.S. approval for the Ocular device, known as OTX-DP are now up in the air.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.
Current Sarepta Chief Medical Officer Ed Kaye is taking over the CEO role on an interim basis until a permanent chief can be found to replace Chris Garabedian.
Will the biotech bubble support the comeback of Introgen Therapeutics, one of the sector's largest disasters?
French investors holding shares of Genfit are having trouble coping with the failure of the company's fatty liver disease drug GFT505.
Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.